Similar Papers

Paper Title
Journal
Date
Author
An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients.
Alberto Talaya ... Carlos Solano
Medical Microbiology and Immunology | VOL. 209
Alberto Talaya, et. al.Alberto Talaya ... Carlos Solano
03 Sep 2019
Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360).
A Erice ... A M Caliendo
Clinical Infectious Diseases | VOL. 37
A Erice, et. al.A Erice ... A M Caliendo
29 Jul 2003
Low Rate of CMV End-Organ Disease in HIV-Infected Patients Despite Low CD4+ Cell Counts and CMV Viremia: Results of ACTG Protocol A5030
D A Wohl ... M A Jacobson
HIV Clinical Trials | VOL. 10
D A Wohl, et. al.D A Wohl ... M A Jacobson
01 Jun 2009
Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir.
Estela Giménez ... Juan Montoro
Transplant Infectious Disease | VOL. 25
Estela Giménez, et. al.Estela Giménez ... Juan Montoro
07 Feb 2023
View more papers

More From: British journal of haematology

Paper Title
Journal
Date
Author
Fibrinogen genotypes and their impact on recurrence of venous thromboembolism and family history: A prospective population-based study.
Ashfaque A Memon ... Kristina Sundquist
British journal of haematology | VOL. -
Ashfaque A Memon, et. al.Ashfaque A Memon ... Kristina Sundquist
19 Jan 2025
CAR T access and outcomes in large B-cell lymphoma according to ethnicity and socioeconomic deprivation in the UK.
Diana Dragoi ... Andrea Kuhnl
British journal of haematology | VOL. -
Diana Dragoi, et. al.Diana Dragoi ... Andrea Kuhnl
16 Jan 2025
Metastatic melanoma presenting with leucoerythroblastic blood film.
Carlo Zaninetti ... Adrian Schwarzer
British journal of haematology | VOL. -
Carlo Zaninetti, et. al.Carlo Zaninetti ... Adrian Schwarzer
15 Jan 2025
JAK2 is a critical therapeutic target in VEXAS syndrome treated with ruxolitinib.
Andrea Ceccardi ... Gabriele Zoppoli
British journal of haematology | VOL. -
Andrea Ceccardi, et. al.Andrea Ceccardi ... Gabriele Zoppoli
15 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.